| bibliographicCitation |
Earl HM, Hiller L, Vallier A, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See M, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, Gounaris I, Mahler–Araujo B, Provenzano E, Chhabra A, Abraham JE, Caldas C, Hall PS, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA, Agarwal R, Algurafi H, Allerton R, Archer C, Armstrong A, Bale C, Barraclough L, Barthakur U, Bedi C, Benstead K, Bloomfield D, Bowen R, Bradley C, Brown J, Butt M, Churn M, Cleator S, Cliff J, Crellin P, Daly M, De Silva-Minor S, Dhadda A, Din O, Down S, Earl H, Eaton D, Eichholz A, Epurescu D, Goh C, Goodman A, Grieve R, Hadaki M, Harper-Wynne C, Harries M, Hayward L, Humphreys A, Innes H, Jafri M, Jegannathen A, Kelleher M, Kristeleit H, Lee D, Lupton S, MacGregor C, Malik Z, Mansi J, Marshall J, McAdam K, McGolick T, Mehra R, Miles D, Mithal N, Moss C, Moss A, Mukesh M, Neal A, Nelmes D, Neville-Webbe H, Newby J, O'Reilly S, Ostler P, Persic M, Pettit L, Raj S, Raja F, Rea D, Reed C, Rigg A, Roe H, Shah N, Simmonds P, Sims E, Smith S, Storey N, Taylor W, Thanvi N, Tipples K, Vaidya J, Varughese M, Vinayan A, Walji N, Waters S, Woodings P, Wright K, Yahya S. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. The Lancet. 2019 Jun;393(10191):2599–612. doi: 10.1016/s0140-6736(19)30650-6. |